Altre lingue Synaptogenix, Inc.

Azioni

SNPX

US87167T3005

Tempo differito Nasdaq Altri mercati azionari 15:35:40 03/06/2024			Variaz. 5gg	Var. 1 gen.
4,6 ^USD	+1,10%		+0,22%	-32,33%

15/05	Synaptogenix, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
09/04	Synaptogenix, Inc. (NasdaqCM:SNPX) ha acquisito una partecipazione sconosciuta in Psyga Bio Ltd da Cannasoul Analytics Ltd.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09/04
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	03/04
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02/11
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23
Top Midday Gainers	13/07/23
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
SYNAPTOGENIX, INC. : Maxim passe à neutre sur le dossier	19/12/22
Sector Update: Healthcare	16/12/22
Top Midday Decliners	16/12/22
Synaptogenix Shares Decline After Proposed Alzheimer's Disease Treatment Misses Primary Endpoint in Phase 2 Study	16/12/22
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	16/12/22
Synaptogenix Announces $15 Million Private Placement	18/11/22
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	05/08/22
Synaptogenix Doses First Patient in Alzheimer's Disease Dose Optimization Clinical Trial; Shares Rise	20/07/22
Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data	20/07/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Synaptogenix, Inc.

Azioni

SNPX

US87167T3005

Altre lingue

Filtri